TKNO at a glance
Alpha Teknova, Inc. (TKNO, SEC CIK 1850902) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 5, 2026 and Form 4 insider filings as recently as July 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Alpha Teknova, Inc. (TKNO) reported revenue of $40.5 million (up 7.4% from FY2024) and a net loss of $17.3 million. Diluted EPS was -$0.32.
- As of June 30, 2026, 18 institutional investment managers tracked by SignalX reported holding Alpha Teknova, Inc. (TKNO) shares worth $21.5 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Gunstream Stephen on March 6, 2026 of 26,000 shares at $2.15 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $40.5M
- +7.4% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 18 funds
- $21.5M · −1 vs prior quarter
- Latest 8-K
- Aug 5, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Custom manufacturing of critical reagents for life sciences, supporting research to commercialization stages
- New emphasis on scaling operations with investment in a new warehouse and distribution facility to improve capacity and efficiency
- Strategic shift: Growth focus through targeted marketing, strategic partnerships, and expanded sales efforts to increase brand awareness and market presence
- Revenue $40.5M in 2025, up $2.8M (7.4%) from 2024; operating loss narrowed to $17.0M from $26.1M in prior year
- Entered $28.245M amended credit facility in March 2025, including $23.245M term loan and $5M working capital, with revenue and cash covenants
Risk Factors
- Regulatory risk: compliance with Second Amended and Restated Credit Agreement net revenue covenant of $39.0M for 2025, minimum cash requirement $8.0M
- Macroeconomic exposure: 94.4% of revenue from U.S. customers, limited international diversification with only $2.3M (5.6%) sales outside U.S. in 2025
- Operational risk: reliance on manufacturing efficiency gains to improve gross margin to 33.2% in 2025 from 26.5% adjusted in 2024
- Competitive risk: reduced R&D spend by 20.4% to $2.2M in 2025 vs $2.8M in 2024, potentially impacting innovation versus peers
- Financial risk: $13.2M outstanding term loan with related $1.1M exit fee and total accumulated deficit of $135.8M as of December 31, 2025
AI summary of the TKNO 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- New AI adoption risk triggered by evaluating AI across manufacturing, quality systems, and customer-facing activities
- Most material update: AI-generated errors, data leakage, and process failures threatening product quality and operations
- Regulatory risk from evolving California and international AI laws, potentially requiring usage limits or causing fines
- Competitive risk from rivals or new entrants deploying AI more effectively
- Profitability risk: net losses of $3.2 million and $7.7 million for the three and six months ended June 30, 2026
AI summary of the TKNO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release issued August 5, 2026, containing detailed results
Item EX-99.1: Item EX-99.1
- Q2 revenue $12.2M, up 18%, with Lab Essentials and Clinical Solutions each growing 18%
- 2026 revenue guidance raised to $45–47M, signaling sustained demand and improved confidence in biotech-market recovery
Item 5.07: Submission of Matters to a Vote of Security Holders
- 89.20% participation, with 47,821,520 shares represented at the June 1 meeting
- J. Matthew Mackowski and Brett Robertson elected as Class II directors through 2029
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Irene Davis retiring from the Board and Nominating Committee at the 2026 annual meeting
- Departure attributed to personal and professional interests, not disagreement with company policies or operations
Item 2.02: Results of Operations and Financial Condition
- Q1 2026 financial results for quarter ended March 31, 2026
- Press release issued May 6, 2026, containing detailed results and management commentary
Item 5.05: Amendments to the Registrant's Code of Ethics
- Board approved amended and restated Code of Business Conduct and Ethics on May 4, 2026
- Updates align compliance practices, clarify provisions, and improve policy cross-references
AI summaries of TKNO 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TKNO
Don't miss the next TKNO filing
- Alerts as it files. A push when TKNO files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TKNO, by share count.
- Ask anything. An AI agent that reads every TKNO filing and answers with sources.
TKNO alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| DEMSKI MARTHA J | J | Jul 14, 2026 | 12,000 | - |
| DEMSKI MARTHA J | J | Jul 14, 2026 | 12,000 | - |
| DEMSKI MARTHA J | A | Jun 1, 2026 | 55,000 | - |
| Vos Alexander | A | Jun 1, 2026 | 55,000 | - |
| ROBERTSON BRETT | A | Jun 1, 2026 | 55,000 | - |
| Gunstream Stephen | Buy | Mar 6, 2026 | 26,000 | $2.15 |
| Lowell Matthew | Buy | Mar 6, 2026 | 40,000 | $2.19 |
| Terrill Damon | A | Feb 15, 2026 | 148,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $37.7M | $40.5M |
| Gross Profit | - | $7.2M | $13.4M |
| Operating Income | - | -$26.1M | -$17.0M |
| Net Income | - | -$26.7M | -$17.3M |
| Gross Margin | - | 19.2% | 33.2% |
| Op. Margin | - | -69.3% | -41.9% |
| Net Margin | - | -70.9% | -42.6% |
| Balance Sheet | |||
| Total Assets | $128.6M | $118.8M | $103.6M |
| Equity | $90.0M | $82.4M | $68.8M |
| ROE | - | -32.5% | -25.1% |
| Per Share | |||
| EPS | - | $-0.57 | $-0.32 |
| Cash Flow | |||
| Operating CF | - | -$12.4M | -$8.6M |
| CapEx | - | $1.1M | $1.1M |
Source: XBRL data in Alpha Teknova, Inc. (TKNO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate TKNO share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 18 | $21.5M |
| Q1 2026 | 19 | $7.7M |
| Q4 2025 | 16 | $8.4M |
| Q3 2025 | 15 | $13.6M |
| Q2 2025 | 18 | $13.8M |
| Q1 2025 | 14 | $7.1M |
| Q4 2024 | 9 | $16.3M |
| Q3 2024 | 7 | $4.7M |
- Vanguard Capital Management LLC+1.17M (+265%)
- BlackRock+163.0K (+23%)
- Wells Fargo & Co+65.3K (+1653%)
- Goldman Sachs Group+53.6K (+45%)
- AQR Capital Management+47.4K (+71%)
- Millennium Management−372.2K (-83%)
- Citadel Advisors LLC−36.8K (-61%)
- Morgan Stanley−18.2K (-16%)
- Northern Trust−5.8K (-6%)
- FMR LLC (Fidelity)−707 (-6%)
- Two Sigma Investments−19.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 116 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TKNO filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 4 | Jul 16, 2026 | - | - | - |
| 4 | Jun 2, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 4 | Jun 2, 2026 | - | - | |
| 8-K | Jun 1, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 6, 2026 | - | Analysis | |
| 4 | Mar 9, 2026 | - | - | - |
| 4 | Mar 9, 2026 | - | - | - |
| 4 | Mar 9, 2026 | - | - | - |
| 10-K | Mar 2, 2026 | Dec 31, 2025 | Analysis | |
| 8-K | Feb 26, 2026 | - | Analysis | - |
| 10-Q | Nov 7, 2025 | Sep 30, 2025 | Analysis | |
| 10-Q | Aug 8, 2025 | Jun 30, 2025 | - | |
| 10-Q | May 9, 2025 | Mar 31, 2025 | - | |
| 10-K | Mar 7, 2025 | Dec 31, 2024 | - | |
| 10-Q | Nov 8, 2024 | Sep 30, 2024 | - | |
| 10-Q | Aug 13, 2024 | Jun 30, 2024 | - | |
| SC 13D | Jul 19, 2024 | - | - | |
| 10-Q | May 13, 2024 | Mar 31, 2024 | - | |
| 10-K | Mar 27, 2024 | Dec 31, 2023 | - | |
| 10-Q | Nov 13, 2023 | Sep 30, 2023 | - | |
| 10-Q | Aug 11, 2023 | Jun 30, 2023 | - |
Related Health Care companies
- CLDX · Celldex Therapeutics, Inc.In Vitro & In Vivo Diagnostic Substances
- IDXX · Idexx LaboratoriesIn Vitro & In Vivo Diagnostic Substances
- NTLA · Intellia Therapeutics, Inc.In Vitro & In Vivo Diagnostic Substances
- LNTH · Lantheus Holdings, Inc.In Vitro & In Vivo Diagnostic Substances
- MYGN · MYRIAD GENETICS INCIn Vitro & In Vivo Diagnostic Substances
- NEOG · NEOGEN CORPIn Vitro & In Vivo Diagnostic Substances
- QDEL · QuidelOrtho CorpIn Vitro & In Vivo Diagnostic Substances
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
TKNO SEC filings: frequently asked questions
Which institutions hold TKNO stock?
As of June 30, 2026, the largest Alpha Teknova, Inc. (TKNO) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($9.2 million), BlackRock ($5.0 million), Bank of America Corp ($1.5 million), Goldman Sachs Group ($977,000), State Street Corp ($937,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was TKNO's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Alpha Teknova, Inc. (TKNO) reported revenue of $40.5 million (up 7.4% from FY2024) and a net loss of $17.3 million. Diluted EPS was -$0.32. The figures come from the XBRL data in the 10-K.
What are the main risks in TKNO's latest 10-K?
In the 10-K filed March 2, 2026, Alpha Teknova, Inc. (TKNO) flagged: Regulatory risk: compliance with Second Amended and Restated Credit Agreement net revenue covenant of $39.0M for 2025, minimum cash requirement $8.0M. Macroeconomic exposure: 94.4% of revenue from U.S. customers, limited international diversification with only $2.3M (5.6%) sales outside U.S. in 2025. (AI summary of the Risk Factors section.)
What did TKNO report in its latest 8-K?
Alpha Teknova, Inc. (TKNO) filed an 8-K on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results for quarter ended June 30, 2026.
What are the latest TKNO SEC filings?
Alpha Teknova, Inc. (TKNO) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 5, 2026 and a Form 4 insider filing on July 16, 2026.
What is TKNO's SEC CIK number?
Alpha Teknova, Inc. (TKNO)'s SEC Central Index Key (CIK) is 1850902. EDGAR lists every TKNO filing under that number.
Ask anything about TKNO
The research agent reads TKNO's filings, financials, insider trades and 13F holders, then answers with sources.